alexa A Review of Two Promising Radiosensitizers in Brain Met
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

A Review of Two Promising Radiosensitizers in Brain Metastases: Rrx-001 and 2-Deoxyglucose

Bryan T. Oronsky1* , Neil C. Oronsky2, Gary R. Fanger1, Arnold L. Oronsky3, Michelle M.C. Lybeck1, Harry E. Lybeck4, Scott Z. Caroen1, Christopher W. Parker1 and Jan Scicinski1
1EpicentRx Inc, 800 W El Camino Real, Suite 180, Mountain View, CA 94040, USA
2CFLS, LLC, 560 South Winchester Boulevard, San Jose, CA 95128, USA
3InterWest Partners, 2710 Sand Hill Road #200, Menlo Park, CA 94025, USA
4Helsinki University, Yliopistonkatu 4, 00100 Helsinki, Finland
Corresponding Author : Bryan T. Oronsky
EpicentRx Inc, 800 W El Camino Real
Suite 180, Mountain View
CA 94040, USA
Tel: (408) 569 3202
Fax: 650-396-4450
E-mail: [email protected]
Received March 01, 2015; Accepted April 24, 2015; Published April 27, 2015
Citation: Oronsky BT, Oronsky NC, Fanger GR, Oronsky AL, Lybeck MMC, et al. (2015) A Review of Two Promising Radiosensitizers in Brain Metastases: Rrx-001 and 2-Deoxyglucose. J Cancer Sci Ther 07:137-141. doi:10.4172/1948-5956.1000338
Copyright: © 2015 Oronsky BT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


The origin of the common phrase “your name is mud” may derive from the ordeal of 19th century physician, Dr. Samuel Mudd, who was perhaps wrongly convicted of conspiracy in the assassination of President Abraham Lincoln. Mudd’s crime may have only been bad luck: Lincoln’s assassin, John Wilkes Booth, allegedly previously unknown to the doctor, had broken his leg and happened across Mudd who, unwisely, as it turned out, set the fracture, and his own subsequent fate, which included life imprisonment with hard labor, making him a potential victim of circumstance rather than the perpetrator of a crime. Mudd’s grandson, also a physician, tried unsuccessfully to clear his grandfather’s widely reviled name, which as a result has remained, both literally and figuratively, Mudd.

This historical analogy highlights the important point that radiosensitizers as a class have been ignored rather than adored due to their failed reputation. Hence, in the field of radiation oncology, the “your name is mud” expression applies to radiation sensitizers, which from hyperbaric oxygen and the nitroimidazoles, to motexafin gadolinium, tirapazamine and efaproxiral have generally overpromised and under delivered with respect to survival treatment benefits in multiple different indications. However, newer non-toxic radiosensitizers on the horizon such as the antienergetic epigenetic redox modulator, RRx-001, that will start a Phase 2 clinical trial with concurrent whole brain radiotherapy (WBRT) in subjects with brain metastases, may finally validate the underlying promise and unrealized potential of these agents. The successful treatment of brain metastases is at least a four-hurdle process involving penetration, retention, selectivity and toxicity. This article will review the mechanism of the radiosensitizers, RRx- 001, and 2-deoxyglucose, as examples or “role models” for therapies that theoretically are able to overcome these substantial in vivo obstacles to successfully treat brain metastases.

It is the thesis of this review that new radiosensitizers are urgently needed and their poor reputation should be overcome.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version